News | August 11, 2024
Zydus Lifesciences Q1 FY25 revenue up 21% YoY to reach Rs. 6,207.5 Cr
Research & Development (R&D) investments for the quarter stood at Rs. 392.5 crore which is 6.3% of its revenues
Research & Development (R&D) investments for the quarter stood at Rs. 392.5 crore which is 6.3% of its revenues
Zydus receives final approval from USFDA for its NDA Zituvimeta, extended-release tablets
The company will closely work with the USFDA to address and respond to the observations in an expeditious manner
USFDA inspects Zydus Lifesciences’ Ahmedabad SEZ Onco manufacturing plant
Zydus Lifesciences receives EIR report from USFDA for API Ahmedabad facility
Zydus’s revenue growth was led by India and EU formulations businesses in addition to that in the emerging markets.
This is the first and only oral once-a-day therapy for testosterone suppression in patients with advanced prostate cancer in India
This PAI-cum-GMP USFDA inspection was conducted from December 14 to December 22, 2023
The company is addressing these observations
The United States Food and Drug Administration (USFDA) conducted an inspection at Gland Pharma Limited API Facility at JNPC, Visakhapatnam
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
